BridgeBio Oncology Therapeutics, Inc.(BBOT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BBOT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), BridgeBio Oncology Therapeutics, Inc. reports net income of $-56.5M, free cash flow of $-44.4M. Top institutional holders of BBOT by reported 13-F value include Cormorant Asset Management, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Omega Fund Management, based on the most recent SEC filings. BBOT trades on the Nasdaq exchange and files with the SEC under CIK 1869105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BridgeBio Oncology Therapeutics, Inc. directly from SEC EDGAR.